279 related articles for article (PubMed ID: 20808793)
1. Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants?
Durrmeyer X; Hovhannisyan S; Médard Y; Jacqz-Aigrain E; Decobert F; Barre J; Alberti C; Aujard Y; Danan C; Baud O
PLoS One; 2010 Aug; 5(8):e12329. PubMed ID: 20808793
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
3. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Ohlsson A; Walia R; Shah S
Cochrane Database Syst Rev; 2008 Jan; (1):CD003481. PubMed ID: 18254020
[TBL] [Abstract][Full Text] [Related]
4. Baseline cardiac output and its alterations during ibuprofen treatment for patent ductus arteriosus in preterm infants.
Hsu KH; Wu TW; Wu IH; Lai MY; Hsu SY; Huang HW; Mok TY; Lee CC; Lien R
BMC Pediatr; 2019 Jun; 19(1):179. PubMed ID: 31167645
[TBL] [Abstract][Full Text] [Related]
5. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Ohlsson A; Shah SS
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD004213. PubMed ID: 31985838
[TBL] [Abstract][Full Text] [Related]
6. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Ohlsson A; Shah SS
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD004213. PubMed ID: 31222841
[TBL] [Abstract][Full Text] [Related]
7. Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants.
Ohlsson A; Walia R; Shah S
Cochrane Database Syst Rev; 2003; (2):CD003481. PubMed ID: 12804469
[TBL] [Abstract][Full Text] [Related]
8. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Ohlsson A; Walia R; Shah S
Cochrane Database Syst Rev; 2005 Oct; (4):CD003481. PubMed ID: 16235321
[TBL] [Abstract][Full Text] [Related]
9. The fate of ductus arteriosus in infants at 23-27 weeks of gestation: from spontaneous closure to ibuprofen resistance.
Dani C; Bertini G; Corsini I; Elia S; Vangi V; Pratesi S; Rubaltelli FF
Acta Paediatr; 2008 Sep; 97(9):1176-80. PubMed ID: 18624987
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.
López-Rodríguez R; Novalbos J; Gallego-Sandín S; Román-Martínez M; Torrado J; Gisbert JP; Abad-Santos F
Pharmacol Res; 2008 Jul; 58(1):77-84. PubMed ID: 18694831
[TBL] [Abstract][Full Text] [Related]
11. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Ohlsson A; Walia R; Shah SS
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD003481. PubMed ID: 32045960
[TBL] [Abstract][Full Text] [Related]
12. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.
Ochoa D; Prieto-Pérez R; Román M; Talegón M; Rivas A; Galicia I; Abad-Santos F; Cabaleiro T
Pharmacogenomics; 2015; 16(9):939-48. PubMed ID: 26122864
[TBL] [Abstract][Full Text] [Related]
13. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Ohlsson A; Walia R; Shah SS
Cochrane Database Syst Rev; 2015 Feb; (2):CD003481. PubMed ID: 25692606
[TBL] [Abstract][Full Text] [Related]
14. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.
Yasar U; Lundgren S; Eliasson E; Bennet A; Wiman B; de Faire U; Rane A
Biochem Biophys Res Commun; 2002 Nov; 299(1):25-8. PubMed ID: 12435384
[TBL] [Abstract][Full Text] [Related]
15. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study.
Heyman E; Morag I; Batash D; Keidar R; Baram S; Berkovitch M
Pediatrics; 2003 Nov; 112(5):e354. PubMed ID: 14595076
[TBL] [Abstract][Full Text] [Related]
16. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study.
Hirt D; Van Overmeire B; Treluyer JM; Langhendries JP; Marguglio A; Eisinger MJ; Schepens P; Urien S
Br J Clin Pharmacol; 2008 May; 65(5):629-36. PubMed ID: 18307541
[TBL] [Abstract][Full Text] [Related]
17. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low-birth-weight infants.
Ohlsson A; Shah PS
Cochrane Database Syst Rev; 2015 Mar; (3):CD010061. PubMed ID: 25758061
[TBL] [Abstract][Full Text] [Related]
18. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
19. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus.
Smith CJ; Ryckman KK; Bahr TM; Dagle JM
Pediatr Res; 2017 Nov; 82(5):776-780. PubMed ID: 28609430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
